Scatena, C. et al. 2021. A Budget Impact Analysis of the VENTANA PD-L1 SP142 Immunohistochemistry Assay Versus the Dako PD-L1 IHC 22C3 Assay in Patients With Advanced or Metastatic Triple-Negative Breast Cancer Treated With Atezolizumab in Combination With Nab-Paclitaxel. Farmeconomia. Health economics and therapeutic pathways. 22, 1 (Jul. 2021). DOI:https://doi.org/10.7175/fe.v22i1.1502.